Dexcom’s CEO claims company has a ‘compelling’ case for broader CGM use

Published on:

Dexcom CEO Kevin Sayer

In a wide-ranging interview, Dexcom’s CEO shared more about the company’s push to prove its continuous glucose monitor can be used both for patients with Type 1 and Type 2 diabetes, and how the device-maker is handling a growing number of competitors. 

Read more    Source: medcitynews.com